Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CCTR on the run. .26 break was huge. Looking for .03+ today. Insiders are buying. A short squeeze on this one could send this to .10+.
Looking for .10+ on CCTR. A short squeeze may send it much higher. gltu
I think that .10 - .20 can be reached with the upcoming short squeeze.
CCTR strong move into the close here. Looks like .024 break and run could be on tap for tomorrow.
CCTR .023 break! Looks like a gapper for tomorrow.
CCTR fake wall @ .022 getting ready to fall.
CCTR .023 setting up for an EOD run and Wednesday gapper.
CCTR headed to .10+ IMO.
Nice pickup on VASO. Bouncing off .20 here.
My VASO closing prediction: .385 with 10,490,500 shares traded. I think we will see a huge buy right before the close (500K shares) Float is 42.5M shares and on track to trade 1/4 of the float (most shares purchased > .25). This one is going MUCH higher IMO.
VASO is replicating the move off news of VSTNQ on 2/26.
Consolidated in high .20's and moved to the 30's near close.
Hit .95 the next day.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48792220&txt2find=vaso
It's just the beginning with VASO, IMO.
Today will most likely be the last opportunity to buy VASO shares for under .30. After this news circulates over the weekend, Monday is going to be fun. JMHO
Not just any product but the first of it's kind!
From today's VASO PR announcing the FDA Clearance:
Dr. Derek Enlander, an NYC Internal Medicine physician commented that "The Vasomedical BIOX(TM) 2301 is the only personal combined system to simultaneously and continuously record and store EKG and blood pressure data for 24 hours. The ability to view these parameters simultaneously, side by side is unique," continued Dr. Enlander, "it gives the physician more useful information to evaluate the patient's cardiovascular status and make appropriate clinical judgment.
The fact that this product offers something others don't in this $8B market gives them an advantage and opportunity to take a good portion of this market share. I am very excited about the huge potential with VASO!
Yup, NITE is letting VASO go. Should be a fun one to watch this afternoon. I still think we see .50+ by EOD w/10M+ shares traded.
Lunchtime is just about over. Time for VASO to fly now.
Real-time Level 2 quote for VASO available here fwiw:
http://www.otcmarkets.com/pink/quote/quote.jsp?symbol=vaso
Here we go! VASO getting ready to bust through .32.
VASO going to .50+ this afternoon on Huge FDA Clearance news IMO. Take advantage of the lunchtime lull to scoop up some shares on the pullback/churn. News has only been out for an hour.
VASO parabolic move coming on .32 break.
Should break .27 easily once this news starts to spread.
Certainly MRSSMITH! t/y and gltu. I think we have a real winner here, with VASO.
Vasomedical Announces FDA 510(k) Clearance on the First Combined ECG Holter and Ambulatory Blood Pressure Monitoring System
Apr 9, 2010 11:27:00 AM
Copyright Business Wire 2010
Close Ad
Email story | Discuss on ZenoBank | View more ads
WESTBURY, N.Y.--(BUSINESS WIRE)-- Vasomedical, Inc. ("Vasomedical") (OTC: VASO.OB), a leader in the non-invasive treatment and management of cardiovascular diseases, today announced the receipt of the US FDA 510(k) clearance on April 2, 2010 to market its Vasomedical-BIOX(TM) Model 2301 Combined ECG Holter and Ambulatory Blood Pressure Monitoring Recorder and Software Analysis System. Last year, the Vasomedical BIOX(TM) Model 1305 Holter Monitor and analysis software received FDA clearance.
Dr. Derek Enlander, an NYC Internal Medicine physician commented that "The Vasomedical BIOX(TM) 2301 is the only personal combined system to simultaneously and continuously record and store EKG and blood pressure data for 24 hours. The ability to view these parameters simultaneously, side by side is unique," continued Dr. Enlander, "it gives the physician more useful information to evaluate the patient's cardiovascular status and make appropriate clinical judgment. Over the past few years, Holter monitors and other ambulatory devices have increased in use, allowing early diagnosis and disease management not only by cardiologists but by general practitioners. I believe this product will have a great impact on the improvement of healthcare quality and reduction of healthcare cost."
"These are the first in a line of Vasomedical-BIOX(TM) ECG Holter and Ambulatory Blood Pressure Monitoring Systems that Vasomedical intends to bring to the marketplace," said Dr. Jun Ma, President and CEO, who further stated that "the introduction of Model 1305 Holter Monitor last year placed Vasomedical into the patient monitoring business with a high quality digital equipment that has enjoyed international success. The Model 2301, however, will make Vasomedical a supplier of ambulatory equipment, because it is so far the only combined ambulatory ECG/blood pressure recording device in the United States. In addition to being a compact device that replaces two separate recorders, it also provides interactive blood pressure recording at times of certain cardiac abnormalities, thus significantly enhancing the diagnostic value of the recorded data while increasing patient comfort and ease of use. Along with our core EECP(R) therapy and patient management products, which include handheld EZ(TM) ECG and EZ(TM) O2 pulse oximeters, Vasomedical continues to expand its presence in the marketplace with innovative and noninvasive products designed to improve patient care and reduce healthcare costs."
About Vasomedical
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP(R) external counterpulsation systems based on the Company's proprietary technology. EECP(R) therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP(R) equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. Additional information is available on the Company's website at www.vasomedical.com.
About BIOX Instruments Co., Ltd.
BIOX Instruments Co., Ltd., based in China, is a strategic partner of Vasomedical. Established in 1993, BIOX conducts research, designs, manufactures, markets and services electrical medical instruments. The core products of BIOX include Holter recorders, ambulatory blood pressure monitors with BIOX proprietary technology and comprehensive analysis software.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate", "believes", "estimate", "expect", "should", "intend", "projects", "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments
Source: Vasomedical, Inc.
----------------------------------------------
Vasomedical
Inc.
Dr. Jun Ma
President and CEO
516-997-4600
or
David Singh
CFO
516-997-4600
or
Investor Relations:
customerservice@vasomedical.com
VASO is going to be a monster this afternoon IMO. Looking for $1+ over the coming days/weeks. This is Huge news!
HLXW on breakout watch! .15 getting hit.
HLXW ^ ticking on light volume this morning. It's only a matter of time before this one takes off. Long overdue!
HLXW setting up for a gap in PM. Huge volume yesterday. Looking for .20+ this week.
All buys going through for HLXW today (light volume). Good news considering all the selling taking place the last couple of weeks. I'm expecting a company update PR next week. It won't take much volume to push this one back to .20+ (once through .15 resistance). Keep on close watch.
HLXW going to be a big mover next week IMO. Selling is finally drying up & bouncing off support, @ .11. The company has been updating their website over the last week or so and new Mgmt is in place. Looking for news next week and a move back to .20+.
HLXW bouncing off .11 here. Bottom is in. Time for a nice reversal IMO.
HLXW upticking easily on light volume here. Looks like the MM's are finally ready to move this one.
Nice flip! Looks like HLXW has the Friday blues. Still looks great for next week, IMO.
Looks like she wants to go again here.
Coming back down now to her resting place...
I guess lots of people bailed HLXW to get some WAMUQ on the cheap today, for the bounce. Can you now buy back into HLXW, with your WAMUQ profits, for the run next week? LOL
I just reread your post and noticed that you saw the post on Yahoo and it wasn't "your daughter" who reported the information. You are still well deserving of the membermark for posting this information over here, on ihub, so quickly. Thanks again!
Great summary. Person marked you for your outstanding DD in getting this 1st hand opinion on the ruling disseminated (based on your daughters/class evaluation of the situation)...I appreciate it!
HLXW .22 break here sends this one to the .30's. This one is going to be fun to watch next week, IMO.
Still waiting for that break of .22 to get the real party started with HLXW. It's coming!
I had chili for lunch so make sure that once that HLXW wind turbine kicks in, you're not down wind!!!